The delayed approval and price setting of Novartis Pharma’s Zolgensma (onasemnogene abeparvovec), a gene therapy for spinal muscular atrophy (SMA) listed in May, has raised questions about how the sakigake designation system should be operated. Despite being designated for the…
HOME > BUSINESS
BUSINESS
- Sanofi Launches Japan’s 1st Humalog Biosimilar
June 30, 2020
- EU Advisory Panel Snubs Daiichi Sankyo Cancer Med Pexidartinib
June 30, 2020
- Takeda to See US$200 Million Operating Loss Tied to Novartis' EU Xiidra Withdrawal
June 30, 2020
- Mitsubishi Tanabe Files Inebilizumab in Japan for NMOSD
June 29, 2020
- Pfizer Japan Boosting Biosimilar Sales Structure with Dedicated Unit, Ups Its Quality Pitch
June 29, 2020
- AstraZeneca in Talks with Daiichi Sankyo, Meiji Group on COVID-19 Vaccine Supplies in Japan
June 29, 2020
- Eisai’s Parkinson’s Med Equfina Gets South Korea Nod
June 26, 2020
- Sosei, AbbVie Link Arms for Inflammatory and Autoimmune Disease Drugs
June 26, 2020
- Carna Biosciences Takes Back Kinase Inhibitor from Canadian Licensee
June 26, 2020
- Japan Sales Rep Promotions in April Tumble 61% YOY: Intage
June 25, 2020
- Takeda’s CEO Pay Tops 2 Billion Yen in FY2019; Old Guard Pitch to Send in External Director Rejected
June 25, 2020
- Orphan Status Granted to Otsuka Gene Therapy, SanBio Cell Program
June 25, 2020
- 7 Authorized Generics in June Listing Target Combined 260 Billion Yen Market; Simultaneous Launches Catching On
June 24, 2020
- Rohto to Launch Stem Cell Clinical Trial for COVID-19 in August, Eyes Conditional OK
June 24, 2020
- Pfizer Japan Draws Up Post-COVID-19 “New Normal Roadmap,” Easing Voluntary Restrictions in Phases
June 24, 2020
- US FDA Accepts Relugolix for Review in Advanced Prostate Cancer
June 24, 2020
- Ayumi Chief Says Contender Debut Will Add Vigor to Enbrel Biosimilar Space, Sees Govt Fee Incentive as Booster
June 23, 2020
- Takeda to Book One-Time Profit Gains after SHP647 Divestment Obligation Cleared
June 23, 2020
- Celgene’s CAR-T Therapy Filed in Japan for B-Cell Lymphoma: BMS
June 23, 2020
- Shionogi Licenses Rapid COVID-19 Diagnostic Methods Developed by 3 Universities
June 23, 2020
ページ
When Jiho surveyed drug makers on the non-sales criteria they use to evaluate reps’ performance, it received a variety of…
Nearly a year after the introduction of the Ministry of Health, Labor and Welfare’s (MHLW) drug promotion guidelines in April…
Advancements in modified oligonucleotide technologies has been the key driver behind a spate of approvals in the oligonucleotide therapeutics space…
Japan’s key reimbursement policy panel on December 20 approved an outline of its FY2020 drug pricing reform next April, with…
The Ministry of Health, Labor and Welfare (MHLW) on November 27 added to the NHI price list Japan’s first biosimilars of Avastin (bevacizumab), Nesp (darbepoetin alfa), and Forteo (teriparatide). The NHI prices of first biosimilars are set at 70% of…
A total of 51 new drugs joined the NHI price list in 2019, which are expected to generate combined peak sales of 373 billion yen, according to Jiho’s tally of data submitted to a key reimbursement policy panel. The relatively…
Some seven years in the making, Japan’s Ministry of Health, Labor and Welfare (MHLW) finally rolled out a cost-effectiveness assessment…
Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…
In a change striking to the very core of the traditional Japanese salaryman, “We are seeing the coronavirus ushering in a new way of working… and I think it’s about time,” says Ivan Tselichtchev, Professor of Economics at the Niigata…